$29.13
+6.2%Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Chief Business Officer
Chief Development Officer
Chief Financial Officer
Compensation
$625,975
Chief Medical Officer
Compensation
$700,858
Chief Scientific Officer
Co-Founder & Independent Director
Compensation
$24,000
President, Chief Executive Officer, Secretary & Director
Compensation
$1,008,568
Senior Vice President of Antibody Engineering & Protein Sciences
Senior Vice President of People & Culture
During the last 12 months, insiders have purchased $2.40M and sold $639K worth of TECX shares, resulting in $1.76M of net buying activity.
0
0.00
18.1K
544.41K
-544K
-$544K
11.0K
235.16K
3.3K
77.63K
+158K
+$158K
62.2K
915.40K
0
0.00
+915K
+$915K
51.0K
1.25M
859
17.02K
+1.2M
+$1.23M
Reicin Alise
Director, Officer: Chief Executive Officer
$498K
Lochner Daniel
Officer: Chief Financial Officer
$275K
Tipirneni Praveen P.
Director
$250K
Springer Timothy A
Director, 10 Percent Owner:
$250K
Donenberg Phillip B.
Director
$250K
Ruddy Marcella K.
Officer: Chief Medical Officer
$363K
Mcnamara Peter
Officer: Chief Scientific Officer
$259K
Reicin Alise
Director, Officer: Chief Executive Officer
$17K
Strong bullish signal with $1.76M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
TECX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 08, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 06, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 22, 2021 | June 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 22, 2020 | June 04, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 26, 2019 | June 11, 2019 | 2019 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.